retatrutide phase 2 study results VisualAbstract: reduces body weight by 17.5% in patients with obesity Retatrutide study sees significant weight

What is the difference between retatrutide and other GLP-1 drugs

Multiple cardiovascular outcomes trials (CVOTs) have shown significant reductions in major adverse cardiovascular events (MACE), which typically includes cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke

Injection Site Reactions: Since many GLP-1 medications are administered via injection, some users may experience redness, itching, or discomfort at the injection site

IUPHAR reviewglucagon-like peptide-1 (GLP-1) and substance use disorders: an emerging pharmacotherapeutic target

Because these are prepared by FDA-registered, inspected compounding pharmacies to meet specific patient needs, they often have a Beyond Use Date (BUD) instead of a traditional expiration date

That is easy to read